Eman A. Al-Rekabi¹, Amina Sabah Hashemi², Rana Talib Al-Muswie³
¹Department of Biology, College of Science, University of Thi-Qar, Iraq
²,³College of Dentistry, University of Thi-Qar, Iraq
*Corresponding author: eman.alrekabi_bio@sci.utq.edu.iq
Received: Nov 14, 2021 / Revised: Nov 28, 2021/ Accepted: Dec 8, 2021
Abstract
The novel coronaviruses disease, namely COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide and resulted in a crucial global health problem. Various studies and meta-analyses have demonstrated that chronic disease, including diabetes mellitus, cardiovascular diseases, and Gastrointestinal manifestations, are considered as risk factors for the disease severity, poor prognosis, and mortality in COVID-19. Although the exact reasons for the association between these comorbidities and disease severity and mortality risk of COVID-19 have not clarified, immune dysregulation and hyperinflammation in these chronic diseases might be contributing factors to the progression of the COVID-19. Furthermore, most of the patients with chronic inflammatory disease have the impairment of immune system and inflammatory response due to underlying pathogenesis of their diseases, and thus they might be prone to SARS-CoV-2 infection. We have focused the attention on most common chronic diseases frequently observed in COVID-19 which may be related to infection and their association with course of COVID-19.
Keywords COVID-19, chronic disease, Diabetes, Cardiovascular Diseases
How to cite this article
Al-Rekabi, E. A., Hashemi, A. S., Al-Muswie, R. T. (2021). COVID-19 and Chronic Diseases.: Pathophysiology, Clinical, Gastrointestinal Manifestation Science Archives, Vol. 2 (4), 320–323. http://dx.doi.org/10.47587/SA.2021.2408
References
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E. (2020). Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit CareMed.
Chen, L., Li, X., Chen, M., Feng, Y., & Xiong, C. (2020). The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular research, 116(6), 1097-1100.
Cristiani, L., Mancino, E., Matera, L., Nenna, R., Pierangeli, A., Scagnolari, C., & Midulla, F. (2020). Will children reveal their secret? The coronavirus dilemma.
Dadashzadeh, N., Farshid, S., Valizadeh, R., Nanbakhsh, M., & Rahimi, M. M. (2020). Acute respiratory distress syndrome in COVID-19. Immunopathologia Persa, 6(2), e16-e16.
Ji, Y., Ma, Z., Peppelenbosch, M. P., & Pan, Q. (2020). Potential association between COVID-19 mortality and health-care resource availability. The Lancet Global Health, 8(4), e480.
Jin, X., Lian, J. S., Hu, J. H., Gao, J., Zheng, L., Zhang, Y. M. & Yang, Y. (2020). Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut, 69(6), 1002-1009.
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med.
Lupia, T., Scabini, S., Pinna, S. M., Di Perri, G., De Rosa, F. G., & Corcione, S. (2020). 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. Journal of global antimicrobial resistance, 21, 22-27.
Maddaloni, E. & Buzzetti, R. (2020). Covid‐19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes/metabolism research and reviews, 36(7), e33213321.
Pyle, C. J., Uwadiae, F. I., Swieboda, D. P. & Harker, J. A. (2017). Early IL-6 signalling promotes IL-27 dependent maturation of regulatory T cells in the lungs and resolution of viral immunopathology. PLoS pathogens, 13(9), e1006640.
Sun, M. L., Yang, J. M., Sun, Y. P., & Su, G. H. (2020). Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases, 43, E014-E014.
Vuorio, A., Watts, G. F. & Kovanen, P. T. (2020). Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. J Intern Med, 287(6), 746-747.
Wang, W., Tang, J. & Wei, F. (2020). Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. Journal of medical virology, 92(4), 441-447.
WHO. (2020). Novel Coronavirus–China. https://www.who.int/csr/don/12- january-2020-novel-coronavirus-china/en/. Accessed 1 Feb 2020.
WHO. (2020). Novel Coronavirus-Japan (ex-China). 2020. https://www.who.int/csr/ don/17-january-2020-novel-coronavirus-japan-ex-china/en/. Accessed 1 Feb.
WMHC. (2020). Wuhan Municipal Health and Health Commission’s Briefing on the Current Pneumonia Epidemic Situation in Our City. http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989. Accessed 1 Feb.
Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., & Shan, H. (2020). Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology, 158(6), 1831-1833.
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine, 46(4), 586-590.
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J. (2020). A novel coronavirus from patients with pneumonia in China. N Engl J Med.https://doi.org/10.1056/NEJMoa2001017.
Licence Article Metadata
This work is licensed under a Creative Commons Attribution 4.0 International License.
